Technical guide & protocol Tech Support

Product Specifications

Sample type/volume

Serum
5 µL
Plasma
5 µL

Hands-on time

40 min

Time-to-result

1 hr 30 min

Homogenous (no wash)

No

Interassay CV

<10%

Intraassay CV

<10%

Instrument

Colorimetric Microplate Reader

Product size

96 Tests

Contents

Pre-coated 96 well plate
Control
SA-HRP Conjugate
Assay Buffer concentrate
Wash Buffer concentrate
Substrate solution
Stop Solution
Adhesive Plate Covers

Shipping conditions

Wet ice

Storage

2-8°C

Protein name

SARS-CoV-2 Spike Protein RBD

Species (tested)

Human

Assay kit format

Competitive ELISA

Detector antibody conjugate

HRP

Label or dye

HRP

About This Kit

The SARS-CoV-2 Neutralizing Ab ELISA is a competitive assay that inversely measures neutralizing antibodies against SARS-CoV-2 Spike RBD in human serum or plasma.

Principle of the method

The Human SARS-CoV-2 Neutralizing Ab ELISA (enzyme-linked immunosorbent assay) is designed to measure the neutralizing portion of anti-SARS-CoV-2 antibodies. A receptor binding domain (RBD) protein is pre-coated in the wells of the supplied microplate. Samples or the positive control are added into the wells and incubated for 30 minutes. Neutralizing antibodies present in a sample that specifically bind to RBD will block the interaction/coverage of RBD with biotinylated ACE2 added for 30 minutes following a wash. Signal from SA-HRP is indirectly proportional to the amount of specific neutralizing antibody present.

Target information

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold symptoms to severe effects including death and respiratory distress. The CoV Spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Of note is the Spike protein receptor-binding domain (RBD, S-RBD) in SARS-CoV-2 Spike protein which binds strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibits significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD in comparison. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?
Let us know so we can reference it here.
Cite this product
guarantee_icon

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more
help_icon

We're here to help

Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.

Contact tech support